InvestRight
Currency
Theme
$1 = ₹95.71 as of 23 Aug
LRCX $269.61 -7.3% MU $924.39 +6.6% DIXON.NS ₹14,507.00 +6.3% SPCX $121.61 +5.7% BLK $1,126.63 +3.5% ORCL $146.47 +3.4% CNL $14.68 +3.0% CVX $193.18 -2.7% PARAS.NS ₹1,377.50 +2.6% ADANIENT.NS ₹3,157.30 +2.6%

SUN PHARMACEUTICAL IND L

SUNPHARMA.NS NSE

Sun Pharmaceutical Ind L looks about 49% overvalued against its cash-flow value. Its growth outlook scores strong; the balance sheet is solid.

$20.05 -0.84% today as of 13 Jul, 4:03 AM
Drug Manufacturers - Specialty & Generic

At a glance

tap a tile to dig in
55 overall score Fair value -49% overvalued vs estimate Health 14/22 checks pass Price · the last month -2.0% Growth 10.4%/yr revenue trend Dividend 0.83% yield P / E 40.1 price / earnings

Otto's verdict

the tiles above, in a line each

Not investment advice — Otto just crunches numbers.

Price trend

-2.0% over the last month · NIFTY 50 +2.0%

2026-07-24 · $20.28 2026-08-21 · $19.88

What think

The market's move: -2.0% over the past year

52-wk low $16.17 high $20.41

Trading 91% up its 52-week range. Price is the market's live vote — not advice.

The snowflake

checks passed on each axis
Value 0% Future 75% Past 50% Health 83% Dividend 67%
  • Value 0/2 checks
  • Future 3/4 checks
  • Past 2/4 checks
  • Health 5/6 checks
  • Dividend 4/6 checks
What does this show?

Five quick health scores — Value, Future, Past, Health and Dividend — each 0–100%. A bigger, more even shape means a stock that scores well across the board; a spiky one is strong on some axes and weak on others.

Learn more on Investopedia →

Fair value

our estimate · not analyst forecast

49% above our estimate — the price sits over what our numbers support.

$20.05 price today $10.17 fair value
How we got there

A 2-stage discounted-cash-flow on free cash flow: grow it at the capped historical trend for five years, fade to a 2.5% long-run rate, discount everything at 9.0%. It's a transparent estimate from past numbers, not a licensed forecast — treat it as one lens, not truth.

What does this show?

Our estimate of what one share is worth based on the cash the business is expected to generate (a discounted-cash-flow model), next to today's price. Below fair value hints undervalued, above hints expensive — it's an estimate, not a guarantee.

Learn more on Investopedia →

Health checks

22 checks run on free data
Show all 22 checks by axis

Value 0/2 passed

  • ⚠ Trading below our fair-value estimate -49% vs our DCF estimate
  • – P/B below industry industry P/B not on the free feed
  • – P/E below industry industry P/E not on the free feed
  • – P/E below peer average peer P/Es land after the next refresh
  • – P/S sane vs its own history needs multi-year P/S (Tier B)
  • ⚠ More than 20% below fair value -49% margin of safety

Future 3/4 passed

  • ✓ Earnings trending up 10.6%/yr over 3yr
  • – Growth beats the industry industry growth not on the free feed
  • ✓ Earnings growth beats the market 10.6%/yr vs market ~9.0%
  • ✓ Revenue trending up 10.4%/yr over 3yr
  • ⚠ Return on equity improving ROE 13.7% vs 15.1% 3yr ago

Past 2/4 passed

  • ✓ Earnings grew over the period 84.7B → 114.8B
  • – High-quality earnings (few one-offs) one-off detection deferred — needs statement detail
  • ⚠ Growth accelerating vs its average latest 5.0%/yr vs 10.6% average
  • ✓ Revenue higher than five years ago 432.8B → 582.2B
  • ⚠ Return on equity above 20% ROE 14.7%

Health 5/6 passed

  • ⚠ Debt/equity falling over time long-term debt/equity 0.0% vs 0.0%
  • ✓ Debt is under 40% of equity debt/equity 6%
  • ✓ Debt well covered by cash flow operating cash flow covers 268.0% of debt
  • ✓ Interest comfortably covered by profit EBIT covers interest 45.6×
  • ✓ Short-term assets cover long-term debt 638.9B vs 22.8B
  • ✓ Short-term assets cover short-term bills 638.9B vs 226.2B

Dividend 4/6 passed

  • ✓ Dividend covered by earnings and cash flow covered by both earnings and free cash flow
  • ✓ Dividend growing over time over 4yr on record
  • ✓ No dividend cut in recent years steady over 4yr on record
  • ✓ Payout ratio under 75% payout 34.5% of earnings
  • ⚠ Yield beats the market yield 0.83% vs market ~1.5%
  • ⚠ Yield in the top quartile of payers yield 0.83% vs 2.54% cut among the 52 payers Otto tracks
What does this show?

Pass/fail rules on the company's finances — debt levels, profitability, cash cover and so on. More greens means a sturdier balance sheet; an n/a just means we didn't have that data point.

Learn more on Investopedia →

Past performance

recent history from Yahoo Finance

Revenue

2023 · 4.5B 2026 · 6.1B

Earnings

2023 · 885.3M 2026 · 1.2B

Free cash flow

2023 · 300.3M 2026 · 920.5M

dashed line = what it'd look like growing at our ~9% market-average benchmark, for comparison

Deeper 10-yr statements are US-only for now — Otto's showing SUNPHARMA.NS's Yahoo figures instead.

What does this show?

How revenue, earnings and free cash flow have grown over the years. Bars rising left-to-right show a growing business; the dashed line is a market-average pace for comparison.

Learn more on Investopedia →

Revenue & expenses

FY 2026
Revenue $6.08B +12% Y/Y Gross profit $4.71B 77% margin Cost of sales $1.38B 23% of revenue Earnings $1.20B 20% margin Expenses $3.51B 58% of revenue SG&A $1.20B 20% of revenue Tax & other $2.31B 38% of revenue
What does this show?

How a company turns sales into profit. Revenue splits into the direct cost of sales and the gross profit left over; from that gross profit come operating costs (R&D, SG&A), tax and interest — what survives is net income. Every figure is also shown as a share of revenue, so you can compare periods and companies of different sizes.

Learn more on Investopedia →

Future

trend, not analyst forecast

Revenue · extended at 10.4%/yr

2023 · 4.5B 2029 · 8.2B projected

Earnings · extended at 10.6%/yr

2023 · 885.3M 2029 · 1.6B projected

Dashed bars just extend the historical trend (capped at ±15%/yr) — the same growth our DCF uses. It's arithmetic on the past, not an analyst forecast; real futures bend.

What does this show?

Solid bars are history; dashed bars simply extend the past growth trend a few years forward — capped so it stays sane. It's a trend line, not an analyst forecast.

Learn more on Investopedia →

Dividend

from cash actually paid, not promises
0.83% current yield · market ~1.5%
4 yrs without a cut, on record
Growing over the saved record
paying out 34.3% of earnings 75% comfort line

Total dividends paid · split-proof, unlike per-share history

2023 · 263.2M 2026 · 411.0M
What does this show?

The share of profit paid back to shareholders as cash. Yield is that cash as a % of the price; the payout gauge shows how much of earnings is paid out (over ~75% can be hard to sustain).

Learn more on Investopedia →

Ownership & insiders

Insider-trade filings come from SEC EDGAR, which covers US companies only — there's no free equivalent for Indian filings yet, so Otto skips this one for SUNPHARMA.NS.

What does this show?

Buys and sells by the company's own directors and officers, from their SEC filings. Insiders sell for many reasons, but clusters of open-market buying can signal confidence.

Learn more on Investopedia →

Competitors

Drug Manufacturers - Specialty & Generic · tap to jump

No competitors listed for SUNPHARMA.NS yet — sign in to add the first one.

What does this show?

A few peers in the same business, each with its own mini snowflake, so you can see how this company stacks up rather than judging it in isolation. Anyone signed in can add a missing competitor — it shows for everyone, marked as user-added.

Learn more on Investopedia →

Leadership

Yahoo Finance · photos & bios via Wikidata

Ranked by title — reporting lines aren't public data. Compensation is the total Yahoo reports; blank means it isn't disclosed there.

In the news

My notes